Generation of bPIV3-vectored PIV and RSV Vaccines

bPIV3 载体 PIV 和 RSV 疫苗的生成

• 批准号: 6534201
• 负责人: AURELIA A HALLER
• 金额: $ 14.77万
• 依托单位: MEDIMMUNE VACCINES, INC.
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-08-04 至 2003-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6534201
• 关键词: Cercopithecidae; Macaca mulatta; Paramyxovirus; active immunization; attenuated microorganism; biotechnology; drug screening /evaluation; genetic manipulation; hamsters; laboratory rat; live vaccine; nonhuman therapy evaluation; respiratory syncytial virus; transfection /expression vector; vaccine development; vector vaccine; virus protein

DESCRIPTION: (Adapted from Applicant's Abstract) Human parainfluenza virus (hPIV) and human respiratory syncytial virus (hRSV) are the main causes of acute respiratory diseases during infancy and early childhood worldwide, often requiring hospitalization. Both viruses are also responsible for serious respiratory tract infections in elderly and immunocompromised individuals. No vaccines are currently available to prevent PlV or RSV infection and disease. Aviron proposes to develop live, attenuated vaccines for prevention of disease caused by hPIV and hRSV. A novel bovine PIV3 (bPIV3) virus rescue system, using this proven safe vaccine, was established successfully at Aviron using reverse genetics. In the Phase I SBIR grant period, we used bPIV3 as a virus vector to express the hPIV3 and hRSV (subgroup A) surface glycoproteins. In phase II of the SBIR program, clinical trial material of the two vaccine candidates will be used to evaluate their attenuation, immunogenicity, and efficacy in primates. In addition, the bPIV3 vector will be employed to generate hPIV 1, 2 and hRSV subgroup B vaccines using novel molecular approaches. Our goal is to generate bPIV3-vectored vaccines for hPIV1, 2, 3 and hRSV (A and B) for human clinical trials and commercial development. PROPOSED COMMERCIAL APPLICATIONS: Aviron's goal is to produce live, attenuated hPIV and hRSV vaccines using bPIV3 as a virus vaccine vector for prevention of diseases caused by hPIV 1, 2, and 3 and hRSV(subgroups A and B) infection. These vaccines will fill a current unmet health need.

描述：（改编自申请人的摘要）人类parainfluenza病毒 （HPIV）和人类呼吸道合胞病毒（HRSV）是主要原因 急性呼吸系统疾病在全球范围内和幼儿期，经常 需要住院。两种病毒也负责严重 老年人和免疫功能低下的个体中的呼吸道感染。不 目前可用于防止PLV或RSV感染和疾病。 Aviron建议开发现场衰减的疫苗以预防疾病 由HPIV和HRSV引起。一种新型的牛PIV3（BPIV3）病毒救援系统，使用 这种经过验证的安全疫苗是在Aviron成功建立的 遗传学。在I期SBIR赠款期间，我们将BPIV3用作病毒向量 表达HPIV3和HRSV（亚组A）表面糖蛋白。在第二阶段的 SBIR计划，两种候选疫苗的临床试验材料将是 用于评估其衰减，免疫原性和灵长类动物的功效。 此外，将采用BPIV3矢量生成HPIV 1、2和HRSV 亚组B疫苗使用新型分子方法。我们的目标是产生 BPIV3向量的HPIV1、2、3和HRSV（a和b）的疫苗用于人类临床 试验和商业发展。 拟议的商业应用： Aviron的目标是使用BPIV3作为病毒疫苗媒介产生活体，减弱HPIV和HRSV疫苗，以预防由HPIV 1、2和3和HRSV引起的疾病（亚组A和B）感染。这些疫苗将满足当前未满足的健康需求。